However, the stability of the linker must be carefully balanced: a too-weak linker may cause premature drug release, while an overly strong linker may hinder drug delivery. various clinical settings. This review provides a comprehensive overview of pre-clinical and clinical data supporting Belantamab mafodotin as a future therapeutic option for RRMM. Keywords:belantamab mafodotin, multiple Mouse monoclonal to PRMT6 myeloma, antibody-drug conjugate == Introduction == Multiple myeloma (MM), the second most prevalent hematological malignancy, accounts for 1% of all cancers.1,2It is marked by the proliferation of malignant plasma cells, resulting in their accumulation in the bone marrow and the overproduction of monoclonal (M) proteins or free light chains.3This overproduction can lead to severe end-organ damage, including anemia, renal insufficiency, hypercalcemia, and lytic bone disease.3In recent years, significant therapeutic advancements, such as proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulators (thalidomide, lenalidomide, pomalidomide), and anti-CD38 monoclonal antibodies (daratumumab, isatuximab), have substantially improved the overall survival rates for MM patients.48 Despite these advancements, MM remains largely incurable, with most patients experiencing relapses and developing resistance to existing therapies.9,10This has underscored the urgent need for new treatments with novel mechanisms of action. Recent innovations in immunotherapy, including chimeric antigen receptor T-cells and T-cell engagers targeting the B-cell maturation antigen (BCMA) on plasma cells, have introduced a new arsenal of therapies for relapsed and refractory MM (RRMM).10,11This paper provides a comprehensive review of the pre-clinical and clinical data published and available on PubMed or other conference proceedings supporting the use of Belantamab Mafodotin, the sole antibody-drug conjugate targeting BCMA, as a promising therapeutic option for RRMM. == B Cell Maturation Antigen (BCMA) Biology == BCMA (B-cell maturation antigen) was first identified in 1992 on chromosome 16p13.1 in malignant human T-cell lymphoma.12It is a type III transmembrane glycoprotein with six conserved cysteines in its extracellular domain name, belonging to the tumor necrosis factor receptor (TNFR) superfamily, specifically TNFRSF17. Predominantly located in a perinuclear structure overlapping the Golgi apparatus, BCMA is also functional around the cell surface.1215BCMA interacts with two related TNFR superfamily members: transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B-cell activation factor receptor (BAFF-R).13,15,16These receptors regulate numerous B cell functions, including proliferation, survival, maturation, and differentiation into plasma cells. Binding of BCMA to its ligands, BAFF and APRIL, activates signaling pathways such as NF-kB, p38, Elk-1, and JNK.14,1719Additionally, a soluble form of BCMA (sBCMA), generated by -secretase, acts as a decoy by neutralizing APRIL, thus inhibiting BCMA pathway activation.20Elevated levels of sBCMA, often found in multiple myeloma (MM) patients, correlate with poor prognosis.21,22Previously, Clofibrate Carpenter et al23found BCMA cDNA in many hematologic tissues, such as blood leukocytes, bone marrow, lymph nodes, tonsils, and spleen. However, BCMA cDNA was not detected in other normal human tissues except for the testis, trachea, and some gastrointestinal organs. As a result, BCMA has been a desirable therapeutic target for treating MM. == Antibody-Drug Conjugate (Adc) Therapy and Their Mechanism of Action == An ADC consists of three essential components: a monoclonal Clofibrate antibody targeting a specific cell surface receptor, a highly potent cytotoxic payload, and a stable linker that connects the antibody to the drug. This advanced therapeutic approach addresses many challenges of traditional chemotherapy.10ADC payloads are designed to be highly potent, often active at picomolar concentrations, to counter the fact that only a small fraction of injected antibodies effectively reach tumor cells. These payloads typically target tubulin or induce DNA damage within targeted cells.2426 The Clofibrate linker between the payload and the antibody is crucial for ADC effectiveness. It controls the release of the cytotoxic drug, directly impacting pharmacodynamics,.